講師
- 籌備委員會成員
- 國際委員會
- 公司展望說明會
- Entrepreneur Pitch
- Session 1&2 – Global Biotech Development
- Session 3 – From Great to Excellent: Develop Taiwan Medical Care
- Session 4 – How to Bring New Drugs to Global Markets?
- Session 5 – Invest for 2024 and Beyond
- Session 6 - BIO Asia–Taiwan 2023 Opening & Award Ceremony
- Session 7 - Sharing Biotech Successes-Taiwan BIO Awardee Showcas
- Session 8 – Crossing Borders, Establishing a Global Biotech Ecos
- Session 9 – New Asian Age
- Session 10 – Clinical Impacts of Precision Health
- Session 11 – Cell and Gene Therapies with Novel Enabling Platfor
- Session 12 – New Modalities to Cure
- Session 13 – Empowering Patient-centric Digital Health
- Session 14 – Robust Manufacture for Cell Therapies and Biologic
- Session 15 – Biodesign for the Future of MedTech
- Satellite Conference
台新藥股份有限公司
Company Info
Name /Formosa Pharmaceuticals Inc.,
Address /8F-6, No. 57, Fuxing N. Rd., Taipei City 105404, Taiwan
Website /www.formosapharma.com
Presenter
Name /Dr. Erick Co
Title /CEO
Email /erickco@formosapharma.com
Telephone /02-2755-7659
Fax /
Mobile /
Company Type
Biotechnology,Pharmaceutical
About the Company
Formosa Pharmaceuticals is a clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.
Brief Description of main products or services
Formosa Pharma's primary objectives are identifying regional/global licensing or co-development partners for our two leading assets:
APP13007: Phase 3 candidate for inflammation and pain after cataract surgery (Phase 2 summary is available).
TSY-0110: Biosimilar of the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).